	US 12,312,638 B2
	Biomarker for diagnosing or predicting reactivity of ovary to FSH and use thereof
Kyung Ah Lee, Seoul (KR); Mi Kyoung Koong, Seoul (KR); and Su Yeon Lee, Pocheon-si (KR)
Assigned to CHA UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, Pocheon-si (KR)
Appl. No. 17/269,714
Filed by CHA UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, Pocheon-si (KR)
PCT Filed Aug. 30, 2019, PCT No. PCT/KR2019/011161 § 371(c)(1), (2) Date Feb. 19, 2021, PCT Pub. No. WO2020/046045, PCT Pub. Date Mar. 5, 2020.
Claims priority of application No. 10-2018-0104044 (KR), filed on Aug. 31, 2018.
Prior Publication US 2021/0404001 A1, Dec. 30, 2021
Int. Cl. C07H 21/02 (2006.01); C12Q 1/6883 (2018.01)

CPC C12Q 1/6883 (2013.01) [C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/178 (2013.01); G01N 2800/367 (2013.01)]

6 Claims

1. A composition for diagnosing or predicting reactivity of an ovary to follicle-stimulating hormone (FSH), comprising an agent for measuring an expression level of microRNA-4463 (miRNA-4463) and microRNA-329-3p, or an expression level of mimic thereof,

wherein the agent is a primer or a probe.